Drug firm Lupin is expecting revenues of up to $150 million (over Rs 780 crore) from its oral contraceptive (OC) segment in the US market by 2013-14, a segment in which it had forayed recently. The firm entered into the OC segment in the US in September this year with the US health regulator approving its generic norethindrone tablets in the strength of 0.35 mg. The company is looking at around $125 million to $150 million from the oral contraceptive market in the US by 2013-14, when its portfolio would be at its peak.
Since its foray, the company has received two more approvals from the US Food and Drug Administration (USFDA) in the OC segment, taking the total approvals to three in the US market. Apart from generic norethindrone tablets, the company has received approvals from the USFDA to market generic versions of LoSeasonique tablets and Femcon Fe respectively. The company's OC segment pipeline consists of 30 filings to the USFDA till date, of which it has already received approval for three generic drugs. According to industry estimates, the US market for oral contraceptives is pegged to be around $4.5 billion.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1797.80 |
Dr. Reddys Lab | 1213.90 |
Cipla | 1486.30 |
Lupin | 2069.95 |
Zydus Lifesciences | 948.70 |
View more.. |